Europe
Galapagos will receive $3.95 billion in upfront cash, as well as a $1.1 billion equity investment from Gilead as the California company gains access to numerous compounds in Galapagos’ pipeline.
One of the big topics presented at the Alzheimer’s Association International Conference (AAIC) 2019 in Los Angeles was the effect of lifestyle on the risk of Alzheimer’s disease.
The companies indicate they hope to continue data analysis to better understand the disease and will present anything relevant at a future scientific meeting.
With a clear vision in mind Iperion Life Sciences Consultancy has taken the next step in realizing her mission.
Despite being the second most common element in the universe helium has an annoying habit of escaping into space.
Company recognized for its leadership in advancing blood-based tests to diagnose cancer
The National Institute of Health Research has announced £135m of funding for new research projects across the UK to tackle some of the biggest health conditions, including dementia.
Anti-Abeta vaccine demonstrates strong safety and preliminary immunogenicity results in subjects with Down syndrome
Leading dementia figures from universities, pharmaceutical companies and charities have identified six gaps in dementia research that present new opportunities to speed up the search for the first life-changing treatment for the condition.
Setting our strategic vision for the next generation TLR9 immunotherapy platform – introducing MOLOGEN’s new CEO Dr. Stefan M. Manth
PRESS RELEASES